Shiva Kumar Mukkamalla, MD
Hematology · Indiana, PANPI 1013268077
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,775 of the $4,443 with a category attached, or 62.5%. 22 manufacturers reported payments, led by Beigene USA, Inc. at 50.6% of the total. Reporting peaked in 2024 at $3,001 and has fallen 92.4% since, to $228 in 2025.
Across 81 payments — averaging $54.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$2K
- Daiichi Sankyo Inc.$545
- Johnson & Johnson$261
- Novartis$221
- Novocure GmbH$200
- Astellas Pharma US Inc$157
- plus $809 from 16 others
What the payments were for
- Consulting fees$2,77562%
- Speaking & faculty fees$2005%
- Food & beverage$1,01823%
- Education$45110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene USA, Inc. | 1 | $2,250 |
| Daiichi Sankyo Inc. | 2 | $545 |
| Johnson & Johnson(2 entities) | 7 | $261 |
| Novartis | 22 | $221 |
| Novocure GmbH | 1 | $200 |
| Astellas Pharma US Inc | 4 | $157 |
| Seagen Inc. | 8 | $130 |
| Incyte Corporation | 1 | $100 |
| AbbVie | 5 | $84 |
| Gilead(2 entities) | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Pfizer | 4 | $54 |
| Merck | 3 | $49 |
| Array Biopharma Inc | 3 | $44 |
| Genentech USA, Inc. | 3 | $42 |
| Boston Scientific | 1 | $37 |
| AstraZeneca | 2 | $30 |
| Amgen | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| GSK | 1 | $19 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,443 in reported general payments places this provider in the 65th percentile of 64 hematology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 55 | $723,165 |
| TagrissoOsimertinib Mesylate | 40 | $693,584 |
| Abiraterone Acetate | 140 | $460,632 |
| OrserduElacestrant Hcl | 17 | $385,678 |
| IbrancePalbociclib | 22 | $346,724 |
| Lenalidomide | 27 | $346,413 |
| RevlimidLenalidomide | 17 | $330,668 |
| XtandiEnzalutamide | 21 | $294,423 |
| XpovioSelinexor | 13 | $252,706 |
| KisqaliRibociclib Succinate | 14 | $238,884 |
| PromactaEltrombopag Olamine | 13 | $237,903 |
| LynparzaOlaparib | 13 | $135,419 |
| VenclextaVenetoclax | 16 | $124,537 |
| XareltoRivaroxaban | 76 | $54,940 |
| EliquisApixaban | 53 | $35,940 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso, Lynparza | $30 | $1,552,168108 claims |
| NovartisKisqali, Promacta | $221 | $476,78727 claims |
| PfizerIbrance, Eliquis | $54 | $382,66375 claims |
| Astellas Pharma US IncXtandi | $157 | $294,42321 claims |
| AbbVieVenclexta | $84 | $124,53716 claims |
| Johnson & JohnsonXarelto | $261 | $54,94076 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 64 hematology providers in Pennsylvania.
Other hematology in Indiana
- Radhakrishnan RamchandrenWest Reading$233K
- Selina LugerPhiladelphia$122K
- Craig SeamanPittsburgh$88K
- Scott DessainPhiladelphia$79K
- Dan VoglPhiladelphia$79K
- Edward StadtmauerPhiladelphia$72K
- Sanaa RizkPhiladelphia$55K
- Robert KaplanPittsburgh$46K
- Douglas CinesPhiladelphia$44K
- Adam CukerPhiladelphia$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.